ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2580

Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block

Robert M. Clancy1, Glenn Fishman1, Colin Phoon1, Marc Halushka2, Tanisha Jackson1, Kimberly Robins1 and Jill P. Buyon1, 1NYU School of Medicine, New York, NY, 2Johns Hopkins University School of Medicine, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Autoimmunity, heart block and mouse model, Macrophage, PD-1

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The most serious manifestation of fetal exposure to maternal anti-Ro antibodies is the development of heart block. This work addresses the hypothesis that fetal disease occurs in the absence of check point inhibition of inflammation initiated by anti-Ro. This study describes a novel murine model in which deficient PD1 signaling exacerbates mild conduction defects induced by anti-Ro and results in histologic evidence of fibrosis and multinucleated giant cells paralleling observations in human autopsies. Accordingly, these data suggest that checkpoint inhibition may play a role in the pathogenesis of CHB.

Methods: To inhibit PD1 signaling, pregnant wild type CD1 mice treated with anti-CD274 (anti-PD1) Abs, or pregnant PD1 knock out (KO) mice were selected. For both models, mice were injected at E12 and E15 with IgG fractions from either a healthy donor or a mother with anti-52Ro, 60Ro and La (anti-Ro) and 3 children with CHB. As controls, other pregnant CD1 mice received CHB IgG or anti-CD274 Abs alone.

Results: To assure access of autoantibodies to the fetal circulation, blood from embryos (N = 14) dissected from the uterus of a CHB IgG treated pregnant CD1 mouse contained antibody reactivities to all Ro/La components, which were not detected in embryos of mothers injected with control IgG. Exposure of mice to CHB IgG resulted in a prolonged PR interval (5.28 + 0.3, p=0.004 vs control), a result not obtained with anti-PDL1 alone (3.39 + 0.3, p=0.69 vs control). Exposure of CD1 mice to CHB IgG + anti-PDL1 resulted in an even more pronounced conduction defect as reflected by lengthening of the PR interval (PR/√RR, 81 total pups) versus Control IgG (11.3 + 0.2 and 3.4+ 0.1, respectively, p<0.0001). Histology of anti-Ro injected mice showed diffuse positive staining using anti-CD274 Abs (for detection of PDL1 ligand) but not isotype control. Injection of the PD1KO mouse with CHB IgG resulted in the most advanced conduction abnormality as reflected by the PR interval (36 total pups) versus Control IgG (16.24 + 1.56 and 4.55+ 0.11, respectively, p<0.0001). In one of the pups in this group, the block resembled retrograde V-A conduction and the heart removed for histologic evaluation. Consistent with autopsies of human fetuses dying with CHB, there was focal injury with myocyte calcifications, multinucleated giant cells and fibrosis, findings never demonstrated in any previous CHB murine model.

Conclusion: Diminished PD1 signaling exacerbates mild conduction defects induced by anti-Ro/La, which supports the hypothesis that checkpoint inhibitors may play a role in the pathogenesis of CHB.


Disclosure: R. M. Clancy, None; G. Fishman, None; C. Phoon, None; M. Halushka, None; T. Jackson, None; K. Robins, None; J. P. Buyon, None.

To cite this abstract in AMA style:

Clancy RM, Fishman G, Phoon C, Halushka M, Jackson T, Robins K, Buyon JP. Exploiting Inhibition of PD1 Signaling in a Murine Model of Anti-SSA/Ro Associated Congenital Heart Block [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/exploiting-inhibition-of-pd1-signaling-in-a-murine-model-of-anti-ssaro-associated-congenital-heart-block/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/exploiting-inhibition-of-pd1-signaling-in-a-murine-model-of-anti-ssaro-associated-congenital-heart-block/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology